Pengobatan Malaria di Perkotaan dan Pedesaan di Indonesia (Analisis Lanjut Riskesdas 2013)

  • Revi Rosavika Kinansi Balai Besar Penelitian dan Pengembangan Vektor dan Reservoir Penyakit, Salatiga,Jalan Hasanudin Nomor123, Kota Salatiga, Jawa Tengah, Indonesia
  • Diana Andriyani Pratamawati Politeknik Kesehatan Kemenkes Yogyakarta, Jalan Tatabumi Nomor 3 Banyuraden, Gamping, Sleman, Daerah IstimewaYogyakarta, Indonesia
  • Rika Mayasari Loka Penelitian dan Pengembangan Kesehatan Pengendalian Penyakit Bersumber Binatang, Baturaja, Jalan Jenderal A. Yani KM.7 Kemelak Baturaja, Baturaja, Ogan Komering Ulu, Sumatera Selatan Indonesia
Keywords: Plasmodium, artemisin based combination therapy, urban, rural, Riskesdas

Abstract

Malaria control in Indonesia still against many challenges, especially in terms of malaria treatment. One of the causes of low coverage of Artemisin Based Combination Therapy (ACT) is that several locations are no longer malaria endemic, being negligent with malaria cases coming from endemic areas, so that patients are not immediately diagnosed as malaria patients. The purpose of this further analysis was to describe malaria treatment based on Plasmodium species associated with access, time, and administration of ACT treatment between urban and rural areas. The method used is descriptive analysis of secondary data from Basic Health Research in 2013 as many as 1,027,763 people by taking the unit of analysis of individuals who have been diagnosed with malaria by health personnel and individuals whose blood test results are positive for malaria. The results of the analysis provide information that in urban and rural areas, the treatment of P. falciparum and P. vivax is classified as good, namely the majority received ACT treatment, the time to receive ACT treatment was within the first 24 hours, and ACT treatment was given within 3 days of being drunk. However, it was found that in rural areas, P. vivax treatment was still not good because the majority did not receive ACT treatment. The implementation of malaria control in areas that are easily accessible and well-targeted are groups that can afford the costs involved in accessing targeted interventions by public subsidized programs. This encourages all regions to have good health services that provide better access to malaria control interventions.

References

1. Kemenkes RI. Epidemiologi malaria di Indonesia. Buletin Jendela Data dan Informasi Kesehatan. Jakarta: Kementerian Kesehatan RI; 2011.

2. World Health Organization. World malaria report 2019. Geneva: WHO; 2019.

3. Kalsum U, Pertiwi DR, Veronica AL, Wulandari A. Determinan yang berhubungan dengan kejadian Malaria di Indonesia Tahun 2016. J Kesmas Jambi [Internet]. 2018;2(1):81–91. Available from: https://www.online-journal.unja.ac.id/jkmj/article/view/6545.

4. Kementerian Kesehatan. Data dan informasi profil kesehatan Indonesia Tahun 2019. 2019th ed. Jakarta: Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia; 2019.

5. Kementerian Kesehatan Indonesia. Profil kesehatan Indonesia Tahun 2019. Jakarta: Kementerian Kesehatan Republik Indonesia; 2019.

6. Lewinsca MY, Raharjo M, Nurjazuli N. Faktor risiko yang mempengaruhi kejadian malaria di Indonesia : review literatur 2016-2020. J Kesehat Lingkung. 2021;11(1):16–28. doi: 10.47718/jkl.v11i1.1339.

7. Kementerian Kesehatan. Profil kesehatan Indonesia 2018. Jakarta: Pusdatin Kemenkes RI; 2019. 229-234 p. Available from: http://www.kemkes.go.id.

8. WHO. World Malaria Report 2018. Geneva:  WHO; 2018.

9. Ditjen PP&PL. Tatalaksana kasus malaria terkini. Jakarta: Kementerian Kesehatan RI; 2016.

10. Kementerian Kesehatan Badan Penelitian dan Pengembangan Kesehatan. Hasil utama RISKESDAS 2018 [Internet]. Jakarta: Kementrian Kesehat Republik Indones; 2018.1–100. Available from: http://www.depkes.go.id/resources/download/info-terkini/hasil-riskesdas-2018.pdf.

11. Rathmes G, Rumisha SF, Lucas TCD, Twohig KA, Python A, Nguyen M, et al. Global estimation of anti-malarial drug effectiveness for the treatment of uncomplicated Plasmodium falciparum malaria 1991–2019. Malar J. 2020;19:1–15. doi: 10.1186/s12936-020-03446-8.

12. Mace KE, Lucchi NW, Tan KR. Malaria surveillance - United States, 2017. MMWR Surveill Summ. 2021;70(2):1–35. doi: 10.15585/mmwr.ss7002a1.

13. Prudence MN, Alessandro U, Donnen P, Hennart P, Porignon D, Ghislain BB, et al. Clinical malaria and nutritional status in children admitted in Lwiro Hospital, Democratic Republic of Congo. Clinical and Experimental Pathology. J Clin Exp Pathol S3:004. doi: 10.4172/2161-0681.S3-004.

14. Haldar K, Bhattacharjee S, Safeukui I. Drug resistance in Plasmodium. Nat Rev Microbiol. 2018;16(1):156–70. doi:10.1038/nrmicro.2017.161.

15. Ronny A, Tjitra E. Artesunat-amodiakuin dan klorokuin untuk pengobatan malaria vivaks di Puskesmas Kopeta, Maumere, Nusa Tenggara Timur, 2007. Media Litbangkes. 2014;24(4):161–8.

16. Kementerian Kesehatan RI. Laporan riset kesehatan dasar tahun 2013. Jakarta: Badan Penelitian dan Pengembangan Kesehatan; 2014.

17. Hasyim H, Dale P, Groneberg D, Kuch U, Muller R. Social determinants of malaria in an endemic area of Indonesia. Malar J. 2019;18(134):1–11. doi: 10.1186/s12936-019-2760-8.

18. Sitohang V, Sariwati E, Fajariyani SB, Hwang D, Kurnia B, Hapsari RK, et al. Malaria elimination in Indonesia: halfway there. Lancet Glob Heal. 2018;6(6):e604-e606. doi: 10.1016/S2214-109X(18)30198-0.

19. Setyaningsih R, Trapsilowati W, Mujiyono M, Lasmiati L. Pengendalian vektor malaria di daerah endemis Kabupaten Purworejo, Indonesia. BALABA. 2018;14(1):1–12. doi: 10.22435/blb.v14i1.290.

20. Asingizwe D, Poortvliet P, Koenraadt C, Van Vliet A, Ingabire C, Mutesa L et al. Role of individual perceptions in the consistent use of malaria preventive measures: Mixed methods evidence from rural Rwanda. Malar J. 2019;18(270). doi: 10.1186/s12936-019-2904-x.

21. Wilson M, Krogstad D, Arinaitwe E, Arevalo-Herrera M, Chery L, Ferreira M, et al. Urban malaria: understanding its epidemiology, ecology, and transmission across seven diverse ICEMR Network Sites. Am J Trop Med Hyg. 2015;93(3_Suppl)):110–23. doi: 10.4269/ajtmh.14-0834.

22. Ipa M, Widawati M, Laksono AD, Kusrini I, Dhewantara PW. Variation of preventive practices and its association with malaria infection in eastern Indonesia: findings from community-based survey. PLoS One. 2020;15(5):1–18. doi:10.1371/journal.pone.0232909.

23. Tatem A, Gething P, Smith D, Hay S. Urbanization and the global malaria recession. Malar J. 2013;12(133):1–10. doi:10.1186/1475-2875-12-133.

24. Khatib RA, Chaki PP, Wang DQ, Mlacha YP, Mihayo MG, Gavana T, et al. Epidemiological characterization of malaria in rural southern Tanzania following China-Tanzania pilot joint malaria control baseline survey. Malar J. 2018;17(292):1–14. doi: 10.1186/s12936-018-2446-7.

25. van der Pluijm RW, Amaratunga C, Dhorda M, Dondorp AM. Triple artemisinin-based combination therapies for malaria – a new paradigm?. Trends Parasitol. 2021;37(1):15–24. doi: 10.1016/j.pt.2020.09.011.

26. Bennett A, Bisanzio D, Yukich JO, Mappin B, Fergus CA, Lynch M, et al. Population coverage of artemisinin-based combination treatment in children younger than 5 years with fever and Plasmodium falciparum infection in Africa, 2003–2015: a modelling study using data from national surveys. Lancet Glob Heal. 2017;5(4):e418–27. doi: 10.1016/S2214-109X(17)30076-1.

30. Achmadi U. Manajemen Penyakit berbasis wilayah. Jakarta: UI Press; 2010.

31. Assebe LF, Kwete XJ, Wang D, Liu L, Norheim OF, Jbaily A, et al. Health gains and financial risk protection afforded by public financing of selected malaria interventions in Ethiopia: an extended cost-effectiveness analysis. Malar J. 2020;19(41):1–10. doi: 10.1186/s12936-020-3103-5.

29. Moru P, Alor K, Daya B. Pengaruh faktor demografi dan riwayat malaria terhadap kejadian malaria. J Berk Epidemiol. 2016;4(3):338–48.

30. Olliaro PL and Bloland PB. Clinical and public health implications of antimalarial drug resistance. In: Rosenthal PJ, editor. Antimalarial chemotherapy: mechanisms of action, resistance, and new directions in drug discovery. Totowa: NJ: Humana Press; 2001. p. 65–83.

31. Whyte I. Antimalarial agents. In: Caravati EM, McGuigan MA, Whyte IM, Dawson AH, Seifert Sam Schinwald S. Medical toxicology. Edisi ke-3. Philadelphia: Lippincott Williams & Wilkins; 2014. p. 466-74.

32. Ashley E, Dhorda M, Fairhust R, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in plasmodium falciparum malaria. N Engl J Med. 2014;371(5):411–23. doi: 10.1056/NEJMoa1314981.

33. Gueye C, Newby G, Hwang J, Phillips A, Whittaker M, MacArthur J, et al. The challenge of arteminisin resistance can only be met by eliminating Plasmodium falciparum malaria across the Greater Mekong subregion. Malar J. 2014;13(286). doi: 10.1186/1475-2875-13-286.

34. Santoso. Evaluasi penggunaan artesunat-amodiakuin (artesdiakuin) pada pengobatan malaria tanpa komplikasi di Puskesmas Penyandingan dan Tanjung Lengkayap Kabupaten OKU. Bul Penelit Kesehat. 2011;39(2):99–109.

35. Fernandez-Becerra C, Sanz S, Brucet M, Stanisic DI, Alves FP, Camargo EP, et al. Naturally-acquired humoral immune responses against the N-and C-termini of the Plasmodium vivax MSP1 protein in endemic regions of Brazil and Papua New Guinea using a multiplex assay. Malar J. 2010;9(29). doi: 10.1186/1475-2875-9-29.

36. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis. 2009 Sep;9(9):555–66. doi: 10.1016/S1473-3099(09)70177-X.

37. Harijanto PN, Nugroho N, Carta A. Gunawan. Malaria: dari molekuler ke klinis. Edisi 2. Jakarta: Penerbit Buku Kedokteran; 2008. 197 p.

38. Simamora D, Fitri LE. Resistensi obat malaria : mekanisme dan peran obat kombinasi obat antimalaria. J Kedokt Brawijaya. 2007;23(2):82–91.

39. Phok S, Lek D. Evidence on anti-malarial and diagnostic markets in Cambodia to guide malaria elimination strategies and policies. Malar J. 2017;16(171). doi:10.1186/s12936-017-1807-y.

40. Kingdom of Cambodia Ministry of Heath. Cambodia Malaria Elimination Action Framework (MEAF) 2016-2020. Phnom Penh; 2016.

41. Adnyana NWD. Kejadian malaria terkait lingkungan pemukiman di Kabupaten Sumba Barat Provinsi Nusa Tenggara Timur. J Ekol Kesehatan. 2015;14(2):89–95.

42. Kementerian Kesehatan RI. Laporan hasil Riset Kesehatan Dasar (RISKESDAS) Tahun 2010. Jakarta: Kementerian Kesehatan RI; 2011. p. 315-317.

43. Rathod PK, McErlean T, Lee PC. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci USA. 1997;94(17):9389–9393. doi: 10.1073/pnas.94.17.9389.

44. Galactionova K, Smith T, de Savigny D, Penny M. State of inequality in malaria intervention coverage in sub-Saharan African countries. BMC Med. 2017;15(185). doi:10.1186/s12916-017-0948-8.

45. Kinansi RR, Mayasari R, Pratamawati DA. Pengobatan malaria kombinasi artemisinin (ACT) di Provinsi Papua Barat tahun 2013. BALABA. 2017;13(1):43–54. doi:10.22435/blb.v13i1.25546.

46. Bria YP, Yeh CH, Bedingfield S. Significant symptoms and nonsymptom-related factors for malaria diagnosis in endemic regions of Indonesia. Int J Infect Dis. 2021;103:194–200. doi: 10.1016/j.ijid.2020.11.177.

47. Kementrian Kesehatan RI. Peraturan Menteri Kesehatan RI No 5 Tahun 2013 tentang Pedoman Tata Laksana Malaria (7 Januari 2013).

48. Kombonglangi RS. Manajemen terapi malaria falciparum yang resisten terhadap klorokuin. J Majority. 2015;4(6):27-30.

49. White NJ. Antimalarial drug resistance. J Clin Inves. 2004;113(8):1084–92. doi: 10.1172/JCI21682.
Published
2021-12-14
How to Cite
1.
Kinansi R, Pratamawati D, Mayasari R. Pengobatan Malaria di Perkotaan dan Pedesaan di Indonesia (Analisis Lanjut Riskesdas 2013). blb [Internet]. 14Dec.2021 [cited 9Dec.2022];17(2):179-90. Available from: https://ejournal2.litbang.kemkes.go.id/index.php/blb/article/view/4443
Section
Articles